On September 13, 2022, ICER released its draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A” This document from Patients Rising Now offers a framework for considering what aspects of the gene therapies for hemophilia included in ICER’s review are important to patients and their families, and how to consider presenting those perspectives. This guide specifically
provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
Guide for Commenting on ICER’s Draft Evidence Report on Gene Therapies for Hemophilia A and B
